Home › Kanser sa Ovary › Alabama › Birmingham
Pag-aaral pangklinika para sa Kanser sa Ovary sa Birmingham, AL
Isang pag-aaral para sa Kanser sa Ovary ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Birmingham. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Nagre-recruitPhase 2
- University of Alabama at Birmingham Cancer Center, Birmingham
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Nagre-recruitPhase 2
- UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital, Birmingham
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Nagre-recruitPhase 2
- University of Alabama at Birmingham (UAB) Hospital /ID# 274793, Birmingham
DESTINY-PANTUMOUR04
Nagre-recruitObservasyonal na pag-aaral
- Research Site, Birmingham
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Nagre-recruitPhase 1/2
- University of Alabama_6th Ave, Birmingham
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Nagre-recruitPhase 3
- University of Alabama at Birmingham, Birmingham
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Nagre-recruitPhase 3
- University of Alabama - Birmingham ( Site 0058), Birmingham
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Nagre-recruitObservasyonal na pag-aaral
- University of Alabama at Birmingham, Birmingham
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Nagre-recruitPhase 2
- The University of Alabama at Birmingham, Birmingham
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Nagre-recruitPhase 1/2
- The University of Alabama, Birmingham
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Nagre-recruitPhase 1
- University of Alabama Birmingham, Birmingham
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Nagre-recruitPhase 3
- University of Alabama at Birmingham ( Site 0006), Birmingham
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Nagre-recruitPhase 1/2
- Children's Hospital of Alabama, Birmingham
Study of NTB-928 in R/R OC
Nagre-recruitPhase 1
- The University of Alabama, Birmingham
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Nagre-recruit
- University of Alabama at Birmingham Cancer Center, Birmingham
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Nagre-recruitPhase 3
- University of Alabama at Birmingham Cancer Center, Birmingham
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Nagre-recruitPhase 1/2
- University of Alabama at Birmingham, Birmingham
The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in Tampons
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
- University of Alabama at Birmingham, Birmingham
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Nagre-recruitPhase 2
- 004, Birmingham
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Nagre-recruitPhase 2
- University of Alabama at Birmingham Womens & Infants Center, Birmingham
Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro
Nagre-recruitPhase 2
- O'Neal Comprehensive Cancer Center at UAB, Birmingham
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Nagre-recruit
- University of Alabama at Birmingham, Birmingham
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Nagre-recruitObservasyonal na pag-aaral
- Massive Bio SYNERGY-AI site, Birmingham
Pag-aaral para sa Kanser sa Ovary sa ibang lungsod
- Houston, TX89 pag-aaral
- New York City, NY69 pag-aaral
- Boston, MA61 pag-aaral
- Los Angeles, CA50 pag-aaral
- Nashville, TN49 pag-aaral
- Arlington, VA46 pag-aaral
- Philadelphia, PA44 pag-aaral
- Columbus, OH39 pag-aaral
- St. Louis, MO38 pag-aaral
- Chicago, IL36 pag-aaral
- San Antonio, TX31 pag-aaral
- Cleveland, OH30 pag-aaral
Iba pang pag-aaral sa Birmingham
- Kanser (lahat ng uri)31 pag-aaral
- Kanser sa Suso24 pag-aaral
- Obesity23 pag-aaral
- Non-Small Cell Lung Cancer22 pag-aaral
- Acute Myeloid Leukemia21 pag-aaral
- Multiple Myeloma18 pag-aaral
- COPD17 pag-aaral
- Sakit sa Puso at Ugat ng Dugo17 pag-aaral
- Type 2 Diabetes16 pag-aaral
- Kanser ng Endometrium16 pag-aaral
- Overweight16 pag-aaral
- Cystic Fibrosis16 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.